Get the Stockscreener App
43.06
0.75%
0.2646
Omnicell Inc stock is traded at $43.06, with a volume of 242.76K.
It is up +0.75% in the last 24 hours and up +26.27% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
See More
Previous Close:
$42.80
Open:
$42.54
24h Volume:
242.76K
Relative Volume:
0.36
Market Cap:
$1.96B
Revenue:
$1.23B
Net Income/Loss:
$20.43M
P/E Ratio:
97.63
EPS:
0.4411
Net Cash Flow:
$95.39M
1W Performance:
+14.59%
1M Performance:
+26.27%
6M Performance:
+24.99%
1Y Performance:
+38.38%
1-Day Range:
$42.19
$43.68
1-Week Range:
$41.12
$46.89
52-Week Range:
$22.66
$55.00
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
43.01 | 1.95B | 1.23B | 20.43M | 95.39M | 0.4411 |
VEEV
Veeva Systems Inc
|
171.10 | 28.03B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
53.45 | 10.16B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
55.48 | 9.87B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.33 | 6.96B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
24.66 | 4.61B | 637.78M | 239.40M | 307.21M | 1.1909 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-26 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-08-26 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Wall Street Analysts See a 41.19% Upside in Omnicell (OMCL): Can the Stock Really Move This High? - Zacks Investment Research
Discipline and Rules-Based Execution in OMCL Response - Stock Traders Daily
Assessing Omnicell (OMCL) Valuation After Q1 Earnings Beat And Higher EPS Guidance - Yahoo Finance
Omnicell (OMCL) Q1 2026 Earnings Transcript - AOL.com
Omnicell Stock Soars 20.94%, Hits Intraday High of $46.85 - Markets Mojo
Omnicell (NASDAQ:OMCL) Raised to Buy at Wall Street Zen - MarketBeat
Omnicell OMCL Q2 2025 Earnings Transcript - AOL.com
A Look at Omnicell Inc (OMCL) After 3.3% Gain -- GF Value $38.55 vs Price $42.80 - GuruFocus
Omnicell (OMCL) Q1 2025 Earnings Transcript - AOL.com
Here's why Omnicell (OMCL) is a strong value stock - MSN
Omnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin Rises - Yahoo! Finance Canada
Vanguard holds 2.27M shares in Omnicell (NASDAQ: OMCL) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Rocket Pharmaceuticals (RCKT) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Shattuck Labs (STTK) - The Globe and Mail
Omnicell Reports Strong Q1 2026 Earnings, Raises Full-Year GuidanceNews and Statistics - IndexBox
Omnicell (OMCL) Q1 EPS Recovery Tests Bullish Margin Improvement Narrative - simplywall.st
Omnicell Earnings Call Shows Profits Surging, Outlook Raised - The Globe and Mail
Omnicell (NASDAQ:OMCL) Shares Down 7.4%Here's Why - MarketBeat
Vanguard (NASDAQ: OMCL) owns 3.24M Omnicell shares, 7.13% stake - Stock Titan
Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer - TipRanks
Omnicell welcomes hospital pharmacy leader Rick Couldry as senior vice president - marketscreener.com
Analyst Reiterates Buy on Omnicell, Citing Once-in-a-Decade Product Cycle Momentum and Margin Strength; Price Target Maintained at $70 - TipRanks
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer - BioSpace
Omnicell names Rick Couldry as senior vice president, chief pharmacy and clinical officer - Fort Worth Report
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing - The Globe and Mail
OMCL Maintained by Keybanc -- Price Target Raised to $70 - GuruFocus
Omnicell Names Rick Couldry Chief Pharmacy and Clinical Officer - Fort Worth Inc.
KeyBanc raises Omnicell stock price target to $70 on growth outlook By Investing.com - Investing.com South Africa
KeyBanc raises Omnicell stock price target to $70 on growth outlook - Investing.com Australia
Omnicell, Inc. (NASDAQ:OMCL) Q1 2026 Earnings Call Transcript - Insider Monkey
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry As Senior Vice President - TradingView
Omnicell Q1 2026 earnings preview - MSN
Omnicell, Inc. Appoints Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer - marketscreener.com
OMCL Q1 Deep Dive: Platform Expansion and Cost Controls Drive Margin Turnaround - StockStory
Omnicell Inc (OMCL) Q1 2026 Earnings Call Highlights: Strong Rev - GuruFocus
Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026 - Quantisnow
Omnicell Q1 Non-GAAP Earnings, Revenue Rise; 2026 Non-GAAP Earnings Outlook Lifted - Moomoo
Omnicell Stock Jumps 21% In A Day, Now Is Not The Time To Buy The Stock - Trefis
Why Omnicell stock trounced the market on Tuesday - MSN
Why Omnicell Stock Trounced the Market on Tuesday - The Motley Fool
Piper Sandler raises Omnicell stock price target on earnings beat By Investing.com - Investing.com Nigeria
Omnicell Q1 2026 Earnings Call Transcript - MarketBeat
A Look at Omnicell Inc (OMCL) After 20.9% Gain -- GF Value $38.0 - GuruFocus
Is It Too Late To Consider Omnicell (OMCL) After Its Recent 45% One Year Surge - simplywall.st
A Look at Omnicell Inc (OMCL) After 20.9% Gain -- GF Value $38.04 vs Price $45.51 - GuruFocus
Omnicell Q1 2026 slides: 112% EPS surge on Titan XT momentum By Investing.com - Investing.com South Africa
Omnicell OMCL Jumps As Titan XT Launch Fuels Momentum - timothysykes.com
Piper Sandler lowers Omnicell stock price target on lower estimates By Investing.com - Investing.com South Africa
Piper Sandler lowers Omnicell stock price target on lower estimates - Investing.com
Omnicell Targets Expansion with Titan XT and OmniSphere Launch - HarianBasis.co
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):